Gain Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY


· · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · ·
Three Months Ended June 30, 2026 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total
Balance as of March 31, 2026	42,488,578	$4,250	$119,970,514	$996,952	$(106,964,739)	$14,006,977
Issuance of shares in at-the-market ("ATM") offering (Note 13)	779,040	78	1,391,281	—	—	1,391,359
Stock-based compensation (Note 14)	—	—	562,466	—	—	562,466
RSU vesting (Note 14)	72,883	7	(7)	—	—	—
Changes in defined benefit pension plan obligation (Note 10)	—	—	—	61,352	—	61,352
Foreign currency translation	—	—	—	(54,552)	—	(54,552)
Net loss	—	—	—	—	(4,675,571)	(4,675,571)
Balance as of June 30, 2026	43,340,501	$4,335	$121,924,254	$1,003,752	$(111,640,310)	$11,292,031


· · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · ·
Six Months Ended June 30, 2026 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total
Balance as of December 31, 2025	42,073,807	$4,209	$119,139,677	$776,869	$(101,356,007)	$18,564,748
Issuance of shares in ATM offering (Note 13)	963,702	96	1,819,046	—	—	1,819,142
Stock-based compensation (Note 14)	—	—	963,499	—	—	963,499
Exercise of warrants (Note 13)	229,710	23	2,039	—	—	2,062
RSU vesting (Note 14)	73,282	7	(7)	—	—	—
Changes in defined benefit pension plan obligation (Note 10)	—	—	—	60,585	—	60,585
Foreign currency translation	—	—	—	166,298	—	166,298
Net loss	—	—	—	—	(10,284,303)	(10,284,303)
Balance as of June 30, 2026	43,340,501	$4,335	$121,924,254	$1,003,752	$(111,640,310)	$11,292,031

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY


· · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · ·
Three Months Ended June 30, 2025 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total
Balance as of March 31, 2025	28,746,041	$2,875	$91,621,667	$(119,865)	$(85,724,966)	$5,779,711
Issuance of shares in ATM offering (Note 13)	1,417,361	142	2,490,779	—	—	2,490,921
Stock-based compensation (Note 14)	31,210	3	530,496	—	—	530,499
Exercise of warrants (Note 13)	576,709	58	—	—	—	58
Changes in defined benefit pension plan obligation (Note 10)	—	—	—	5,934	—	5,934
Foreign currency translation	—	—	—	698,014	—	698,014
Net loss	—	—	—	—	(5,809,087)	(5,809,087)
Balance as of June 30, 2025	30,771,321	$3,078	$94,642,942	$584,083	$(91,534,053)	$3,696,050


· · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · ·
Six Months Ended June 30, 2025 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total
Balance as of December 31, 2024	27,132,588	$2,713	$88,779,318	$(247,549)	$(81,194,908)	$7,339,574
Issuance of shares in ATM offering (Note 13)	2,512,062	251	4,909,989	—	—	4,910,240
Stock-based compensation (Note 14)	95,069	9	953,635	—	—	953,644
Exercise of warrants (Note 13)	1,031,602	105	—	—	—	105
Changes in defined benefit pension plan obligation (Note 10)	—	—	—	10,760	—	10,760
Foreign currency translation	—	—	—	820,872	—	820,872
Net loss	—	—	—	—	(10,339,145)	(10,339,145)
Balance as of June 30, 2025	30,771,321	$3,078	$94,642,942	$584,083	$(91,534,053)	$3,696,050

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.